{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:30:37Z","timestamp":1793035837870,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012754","name":"Horizon Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001683","name":"Horizon Foundation for New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.semarthrit.2019.11.009","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T11:56:14Z","timestamp":1573818974000},"page":"444-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol"],"prefix":"10.1016","volume":"50","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0002","series-title":"Chapter 16 - Overview of gout therapy strategy and targets, and the management of refractory disease. in: terkeltaub R, ed. gout & other crystal arthropathies","first-page":"194","author":"Liot\u00e9","year":"2012"},{"issue":"16","key":"10.1016\/j.semarthrit.2019.11.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009328","article-title":"Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease","volume":"7","author":"Pagidipati","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.11.009_bib0004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/ar2761","article-title":"Gout Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?","volume":"11","author":"Gaffo","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.11.009_bib0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.11.009_bib0006","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","article-title":"Association of chronic kidney disease with allopurinol use in gout treatment","volume":"178","author":"Vargas-Santos","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0007","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/pcan.2017.14","article-title":"Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study","volume":"20","author":"Shih","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5p1","key":"10.1016\/j.semarthrit.2019.11.009_bib0008","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1399-5618.2006.00363.x","article-title":"Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial","volume":"8","author":"Akhondzadeh","year":"2006","journal-title":"Bipolar Disord"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.11.009_bib0009","first-page":"595","article-title":"Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels","volume":"19","author":"Beutler","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-2952(63)90012-1","article-title":"Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase","volume":"12","author":"Elion","year":"1963","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0011","first-page":"1207","article-title":"Relationship between metabolic fates and antitumor activities of thiopurines","volume":"23","author":"Elion","year":"1963","journal-title":"Cancer Res"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0012","article-title":"NobelPrize.org","author":"Facts","year":"2019","journal-title":"Nobel Media AB"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2008.00065.x","article-title":"Allopurinol for pain relief: more than just crystal clearance?","volume":"156","author":"Connor","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.rdc.2014.01.013","article-title":"Emerging therapies for gout","volume":"40","author":"Edwards","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192781","article-title":"Promising effects of xanthine oxidase inhibition by allopurinol on autonomic heart regulation estimated by heart rate variability (HRV) analysis in rats exposed to hypoxia and hyperoxia","volume":"13","author":"Zajaczkowski","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0016","first-page":"35","article-title":"Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions","volume":"147","author":"Pea","year":"2005","journal-title":"Contrib Nephrol"},{"issue":"8","key":"10.1016\/j.semarthrit.2019.11.009_bib0017","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"10.1016\/j.semarthrit.2019.11.009_bib0018","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"issue":"6586","key":"10.1016\/j.semarthrit.2019.11.009_bib0019","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/bmj.294.6586.1504","article-title":"Use and abuse of allopurinol","volume":"294","author":"Cameron","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.11.009_bib0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2125.1996.03116.x","article-title":"Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects","volume":"41","author":"Graham","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0021","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","article-title":"The pharmacokinetics of oxypurinol in people with gout","volume":"74","author":"Stocker","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2019.02.005","article-title":"Adenosine and lipids: a forced marriage or a love match?","author":"Rouquette","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.11.009_bib0023","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/ATVBAHA.111.226845","article-title":"Regulation of neutrophil function by adenosine","volume":"32","author":"Barletta","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0024","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0306-3623(96)00169-3","article-title":"Purines and neutrophil leukocytes","volume":"28","author":"Fredholm","year":"1997","journal-title":"Gen Pharmacol Vascul Syst"},{"issue":"7261","key":"10.1016\/j.semarthrit.2019.11.009_bib0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.11.009_bib0026","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd2638","article-title":"Adenosine receptors: therapeutic aspects for inflammatory and immune diseases","volume":"7","author":"Hask\u00f3","year":"2008","journal-title":"Nature Rev Drug Discov"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.11.009_bib0027","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/keq045","article-title":"Neutrophil function in inflammation and inflammatory diseases","volume":"49","author":"Wright","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0028","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1100\/tsw.2011.22","article-title":"Anti-inflammatory and immunosuppressive effects of the A2AAdenosine receptor","volume":"11","author":"Milne","year":"2011","journal-title":"Sci World J"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0029","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1124\/jpet.105.096016","article-title":"Adenosine inhibits tumor necrosis factor- release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor","volume":"317","author":"Kreckler","year":"2005","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2019.11.009_bib0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-2999(83)90026-2","article-title":"Dipyridamole inhibition of adenosine metabolism in human blood","volume":"93","author":"Klabunde","year":"1983","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5049\/EBP.2014.12.1.1","article-title":"Dual role as anti-oxidantand pro-oxidant","volume":"12","author":"Kang","year":"2014","journal-title":"Electrol Blood Press"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.11.009_bib0032","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1073\/pnas.78.11.6858","article-title":"Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis","volume":"78","author":"Ames","year":"1981","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0033","first-page":"37","article-title":"Free radical scavenging, DNA protection, and inhibition of lipid peroxidation mediated by uric acid","volume":"35","author":"Stinefelt","year":"2005","journal-title":"Ann Clin Lab Sci"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.11.009_bib0034","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/95.10.691","article-title":"Uric acid: an important antioxidant in acute ischaemic stroke","volume":"95","author":"Waring","year":"2002","journal-title":"QJM"},{"issue":"12","key":"10.1016\/j.semarthrit.2019.11.009_bib0035","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/mds.22139","article-title":"Uric acid in parkinson\u2019s disease","volume":"23","author":"Schlesinger","year":"2008","journal-title":"Movement Disord"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.11.009_bib0036","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: the oxidant-antioxidant paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotid Nucleic Acids"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/S0197-0186(00)00034-6","article-title":"Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors","volume":"38","author":"Cunha","year":"2001","journal-title":"Neurochem Int"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.11.009_bib0038","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0301-0082(03)00050-9","article-title":"Adenosine in the spinal cord and periphery: release and regulation of pain","volume":"69","author":"Sawynok","year":"2003","journal-title":"Prog Neurobiol"},{"issue":"14","key":"10.1016\/j.semarthrit.2019.11.009_bib0039","first-page":"1857","article-title":"Role of adenosine receptors in the anti-nociceptive effects of allopurinol in mice","volume":"17","author":"Essawy","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"16","key":"10.1016\/j.semarthrit.2019.11.009_bib0040","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2019.11.009_bib0041","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3959(01)00435-3","article-title":"Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor","volume":"96","author":"Jarvis","year":"2002","journal-title":"Pain"},{"issue":"1\u20133","key":"10.1016\/j.semarthrit.2019.11.009_bib0042","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.12.029","article-title":"Treatment with the xanthine oxidase inhibitor, allopurinol, improves nerve and vascular function in diabetic rats","volume":"561","author":"Inkster","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0043","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4370490","article-title":"Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy","volume":"2016","author":"Miric","year":"2016","journal-title":"J Diabetes Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0044","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1476-5381.2008.00025.x","article-title":"Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1adenosine receptors","volume":"156","author":"Schmidt","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF02788381","article-title":"Does allopurinol reduce pain of chronic pancreatitis?","volume":"22","author":"Banks","year":"1997","journal-title":"Int J Pancreatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.11.009_bib0046","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF00914193","article-title":"Elevated levels of xanthine oxidase in serum of patients with inflammatory and autoimmune rheumatic diseases","volume":"17","author":"Miesel","year":"1993","journal-title":"Inflammation"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.11.009_bib0047","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/BF01535258","article-title":"Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood","volume":"18","author":"Miesel","year":"1994","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0048","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000139330","article-title":"Effect of high lipid diet and allopurinol on the development of experimentally induced arthritis in rats","volume":"51","author":"Yossif","year":"1995","journal-title":"Pharmacology"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.11.009_bib0049","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00392-007-0636-3","article-title":"Allopurinol improves endothelial function and reduces oxidant-inflammatory enzyme of myeloperoxidase in metabolic syndrome","volume":"97","author":"Yiginer","year":"2007","journal-title":"Clinic Res Cardiol"},{"issue":"22","key":"10.1016\/j.semarthrit.2019.11.009_bib0050","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0051","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","article-title":"Allopurinol improves endothelial dysfunction in chronic heart failure","volume":"106","author":"Farquharson","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.11.009_bib0052","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1161\/01.ATV.0000258415.32883.bf","article-title":"Angiotensin II induces endothelial xanthine oxidase activation","volume":"27","author":"Landmesser","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0053","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jim-2018-000774","article-title":"Case\u2013control study examining the association between allopurinol use and ischemic cerebrovascular disease","volume":"67","author":"Lai","year":"2018","journal-title":"J Investig Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.11.009_bib0054","doi-asserted-by":"crossref","first-page":"R1697","DOI":"10.1152\/ajpregu.1999.277.6.R1697","article-title":"Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease","volume":"277","author":"Heunks","year":"1999","journal-title":"Am J Physiol-Regulat Integrat Comparat Physiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0055","doi-asserted-by":"crossref","DOI":"10.1111\/j.1478-3231.2006.01382.x","article-title":"Allopurinol, oxidative stress and intestinal permeability in patients with cirrhosis: an open-label pilot study","volume":"27","author":"Spahr","year":"2007","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.11.009_bib0056","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.11.009_bib0057","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS function in redox signaling and oxidative stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr Biol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0058","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1089\/ars.1999.1.3-371","article-title":"The thermodynamics of xanthine oxidoreductase catalysis","volume":"1","author":"Sanders","year":"1999","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0059","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1152\/physrev.00018.2001","article-title":"Free radicals in the physiological control of cell function","volume":"82","author":"Dr\u00f6ge","year":"2002","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.intimp.2004.01.022","article-title":"Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders","volume":"4","author":"Namazi","year":"2004","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"10.1016\/j.semarthrit.2019.11.009_bib0061","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1161\/01.CIR.101.18.2206","article-title":"Investigation into the sources of superoxide in human blood vessels","volume":"101","author":"Berry","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0062","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/282059","article-title":"The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease","volume":"2009","author":"Higgins","year":"2009","journal-title":"Cardiovasc Psychiatry Neurol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0063","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/toxsci\/kfi101","article-title":"Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells","volume":"85","author":"Lee","year":"2005","journal-title":"Toxicol Sci"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.11.009_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/chin.200509210","article-title":"Pharmacokinetics\/Pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man","volume":"36","author":"Yamada","year":"2005","journal-title":"ChemInform"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2004.05768.x","article-title":"Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors","volume":"150","author":"Mizuno","year":"2004","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0066","first-page":"94","article-title":"Effect of allopurinol on oxidative stress and hypoxic adaptation response during surgical correction of tetralogy of fallot","volume":"45","author":"Rachmat","year":"2013","journal-title":"Acta Med Indones"},{"issue":"12","key":"10.1016\/j.semarthrit.2019.11.009_bib0067","doi-asserted-by":"crossref","first-page":"e29004","DOI":"10.1371\/journal.pone.0029004","article-title":"Pivotal role of toll-like receptors 2 and 4, its adaptor molecule myd88, and inflammasome complex in experimental tubule-interstitial nephritis","volume":"6","author":"Correa-Costa","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0068","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbagen.2011.09.018","article-title":"Protective effects of allopurinol against acute liver damage and cirrhosis induced by carbon tetrachloride: modulation of NF-\u03baB, cytokine production and oxidative stress","volume":"1820","author":"Aldaba-Muruato","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) - Gen Subj"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0069","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/BF00180017","article-title":"The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor","volume":"350","author":"Olah","year":"1994","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.11.009_bib0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0192-0561(00)00018-7","article-title":"The effects of allopurinol on immune function in normal BALB\/c and SCID mice","volume":"22","author":"Kato","year":"2000","journal-title":"Int J Immunopharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0071","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-3083.1985.tb01853.x","article-title":"Purine metabolic enzymes in lymphocytes","volume":"22","author":"Kurashige","year":"1985","journal-title":"Scand J Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0072","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/112067210301300210","article-title":"Immunological effects of allopurinol in the treatment of experimental autoimmune uveitis (EAU) after onset of the disease","volume":"13","author":"Grus","year":"2003","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.11.009_bib0073","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.crohns.2010.02.009","article-title":"Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD","volume":"4","author":"Govani","year":"2010","journal-title":"J Crohn\u2019s and Colitis"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0074","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00295","article-title":"Allopurinol reduces antigen-specific and polyclonal activation of human T cells","volume":"3","author":"P\u00e9rez-Mazliah","year":"2012","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0075","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/eji.200940168","article-title":"Signaling by ROS drives inflammasome activation","volume":"40","author":"Martinon","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0076","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.freeradbiomed.2013.08.178","article-title":"NLRP3 inflammasome activation in d-galactosamine and lipopolysaccharide-induced acute liver failure: role of heme oxygenase-1","volume":"65","author":"Kim","year":"2013","journal-title":"Free Rad Biol Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.11.009_bib0077","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1038\/cddis.2012.144","article-title":"ATP release and purinergic signaling: a common pathway for particle-mediated inflammasome activation","volume":"3","author":"Riteau","year":"2012","journal-title":"Cell Death Dis"},{"issue":"5876","key":"10.1016\/j.semarthrit.2019.11.009_bib0078","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.1156995","article-title":"Innate immune activation through nalp3 inflammasome sensing of asbestos and silica","volume":"320","author":"Dostert","year":"2008","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.11.009_bib0079","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bph.12226","article-title":"Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats","volume":"169","author":"Wang","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2019.11.009_bib0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.40.3.245","article-title":"Acute adverse reactions attributed to allopurinol in hospitalised patients","volume":"40","author":"McInnes","year":"1981","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.11.009_bib0081","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The dress syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.11.009_bib0082","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0083","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.11.009_bib0084","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.11.009_bib0085","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.semarthrit.2019.11.009_bib0086","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/bjd.15832","article-title":"Cost-effectiveness of HLA-B*15:02 screening in Malaysia","volume":"177","author":"Plumpton","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.11.009_bib0087","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/rheumatology\/kex253","article-title":"Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout","volume":"56","author":"Plumpton","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2019.11.009_bib0088","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2019.11.009_bib0089","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.151476","article-title":"Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions","volume":"44","author":"Ke","year":"2017","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.11.009_bib0090","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/acr.22409","article-title":"Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea","volume":"67","author":"Park","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2019.11.009_bib0091","doi-asserted-by":"crossref","unstructured":"Ponzo MG, Miliszewski M, Kirchhof MG, Keown PA, Dutz JP. HLA-B*58:01 genotyping to prevent cases of dress and sjs\/ten in east asians treated with allopurinol-a Canadian missed opportunity. J Cutan Med Surg2019:1203475419867599 [published Online First: Epub Date]. doi: 10.1177\/1203475419867599.","DOI":"10.1177\/1203475419867599"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219306900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219306900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:01:24Z","timestamp":1758733284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017219306900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0049017219306900"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.009","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}